Company announcement No. 7
Extraordinary dividend of 6.54 DKK per share to be paid on May 20, 2021
Today, the Board of Directors of Chr. Hansen Holding A/S has decided to declare an extraordinary dividend of EUR 116 million, or 6.54 DKK per share with an ex-dividend date of May 18, 2021. The dividend will be paid on May 20, 2021.
The extraordinary dividend follows the completion of the divestment of Natural Colors to EQT and is equivalent to a normalized ordinary dividend for 2019/20, and consistent with the decision by the Annual General Meeting in November 2020 to not pay out an ordinary dividend at the time.
For further information please contact:
Anders Mohr Christensen, Head of Investor Relations, Tel: +45 2515 2364
Annika Stern, Senior Investor Relations Officer, Tel: +45 2399 2382
Yannick Vanderveeren, Head of Media Relations, Tel: +45 2068 6425
About Chr. Hansen
Chr. Hansen is a global, differentiated bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. At Chr. Hansen we are uniquely positioned to drive positive change through microbial solutions. We have worked for over 145 years to enable sustainable agriculture, cleaner labels and healthier living for more people around the world. Our microbial and fermentation technology platforms, including our broad and relevant collection of around 40,000 microbial strains, have game-changing potential. Matching customer needs and global trends we continue to unlock the power of good bacteria to respond to global challenges such as food waste, global health and the overuse of antibiotics and pesticides. As the world’s most sustainable food ingredients company, we touch the lives of more than 1 billion people every day. Driven by our legacy of innovation and curiosity to pioneer science, our purpose – To grow a better world. Naturally. – is at the heart of everything we do.
Upcoming Life Sciences Events
- October 2021
- BIO-Europe® 2021
- Online: AusBiotech 2021 & Australia Biotech Invest & Partnering
- November 2021
- Pharma-Biotech Product & Company Valuation with Dr. P Frei